Skip to main content
  • Editorial: Blinded by the Lights: OCT-Guidance for Implantation of Magnesium-Based Bioresorbable Scaffolds?

    Bioresorbable scaffolds (BRS) were developed as break-through technology to overcome drawbacks of drug-eluting stents (DES), which permanently remain in the vessel wall upon implantation. The most widely used polymeric BRS, Absorb bioresorbable vascular scaffold (Abbott Vascular, Santa Clara, California) (Absorb BVS), was thoroughly examined in a number of clinical trials. Despite its favorable outcome in early clinical investigation, randomized controlled trials (RCT) showed a significantly higher incidence of scaffold thrombosis (ScT) in Absorb BVS than in metallic DES [1] . Owing to sustained late scaffold failure in clinical practice, the manufacturer decided to withdraw it from further commercialization. BRS based on metal alloys have been developed since the late 1990s, and there was strong believe that the similarity in metallurgy compared with existing DES technology would enable sufficient technological performance during percutaneous coronary intervention (PCI), and overcome hazardous material effects observed during degradation of polymeric BRS.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details